UC Riverside UC Riverside Previously Published Works
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
United States Patent (19) 11 Patent Number: 5,627,195 Hu 45 Date of Patent: May 6, 1997
USOO5627195A United States Patent (19) 11 Patent Number: 5,627,195 Hu 45 Date of Patent: May 6, 1997 54 TREATMENT FOR OCULAR Ferrante, et al., Tetrandrine, a Plant Alkaloid, Inhibits the NFLAMMATON Production of Tumour Necrosis Factor-Alpha (Cachectin) by Human Monocytes, Clin, exp. Immunol. 80:232–235 75 Inventor: Shixing Hu, Cambridge, Mass. (1990). Kondo, et al., Inhibitory Effect of Bisbenzylisoquinoline 73) Assignee: Massachusetts Eye and Ear Alkaloids on the Quick Death of Mice Treated with BCG/ Infirmary, Boston, Mass. LPS, Chem. Pharm. bull. 38(10):287-2889 (1990). Ph.D. dissertation of Shixing Hu, Sun Yat-Sen University of 21 Appl. No.: 420,244 Medical Sciences, Guang Zhou, Guang Dong China, 1989. 22 Filed: Apr. 11, 1995 Seow, et al. In Vitro Immunosuppressive Properties of Teh Plant Alkaloid Tetrandrine. Int. Archs Allergy appl. Immun. [51] Int. Cl. ... A61K 31/445 85:410-415 (1988). 52 514/321: 514/912 Rao. et al., Modulation of Lens-Induced Uvetis by Super 58 Field of Search ...................................... 54/321, 912 oxide Dismutase, Opthlalmic Res. 18:41-46 (1986). Abal et al., Clinical Evaluation of Berberine in Mycotic 56 References Cited Infections, Ind. J. Ophthalm. 34:91-2 (1986). FOREIGN PATENT DOCUMENTS Mohan, et al. Berberine: An Indigenous Drug in Experi mental Herpetic Uveitis. Ind.J. Ophthalm. 31:65-68 (1983). 46-21396 6/1971 Japan. Yao Hsueh Tung Pao 1983; 18:31-36 The Natural Sources 3-44323 2/1991 Japan. and Biological Activities of Bisbenzylisoquinoline (BBI) 4–99723 3/1992 Japan. Alkaloids. OTHER PUBLICATIONS Babbar, et al., Effect of Berberine Chloride Eye Drops on Marshall, et al. -
Analytical Reference Standards
Cerilliant Quality ISO GUIDE 34 ISO/IEC 17025 ISO 90 01:2 00 8 GM P/ GL P Analytical Reference Standards 2 011 Analytical Reference Standards 20 811 PALOMA DRIVE, SUITE A, ROUND ROCK, TEXAS 78665, USA 11 PHONE 800/848-7837 | 512/238-9974 | FAX 800/654-1458 | 512/238-9129 | www.cerilliant.com company overview about cerilliant Cerilliant is an ISO Guide 34 and ISO 17025 accredited company dedicated to producing and providing high quality Certified Reference Standards and Certified Spiking SolutionsTM. We serve a diverse group of customers including private and public laboratories, research institutes, instrument manufacturers and pharmaceutical concerns – organizations that require materials of the highest quality, whether they’re conducing clinical or forensic testing, environmental analysis, pharmaceutical research, or developing new testing equipment. But we do more than just conduct science on their behalf. We make science smarter. Our team of experts includes numerous PhDs and advance-degreed specialists in science, manufacturing, and quality control, all of whom have a passion for the work they do, thrive in our collaborative atmosphere which values innovative thinking, and approach each day committed to delivering products and service second to none. At Cerilliant, we believe good chemistry is more than just a process in the lab. It’s also about creating partnerships that anticipate the needs of our clients and provide the catalyst for their success. to place an order or for customer service WEBSITE: www.cerilliant.com E-MAIL: [email protected] PHONE (8 A.M.–5 P.M. CT): 800/848-7837 | 512/238-9974 FAX: 800/654-1458 | 512/238-9129 ADDRESS: 811 PALOMA DRIVE, SUITE A ROUND ROCK, TEXAS 78665, USA © 2010 Cerilliant Corporation. -
Accepted Version
Article Metabolomics identifies a biomarker revealing in vivo loss of functional ß-cell mass before diabetes onset LI, Lingzi, et al. Abstract Identification of pre-diabetic individuals with decreased functional ß-cell mass is essential for the prevention of diabetes. However, in vivo detection of early asymptomatic ß-cell defect remains unsuccessful. Metabolomics emerged as a powerful tool in providing read-outs of early disease states before clinical manifestation. We aimed at identifying novel plasma biomarkers for loss of functional ß-cell mass in the asymptomatic pre-diabetic stage. Non-targeted and targeted metabolomics were applied on both lean ß-Phb2-/- mice (ß-cell-specific prohibitin-2 knockout) and obese db/db mice (leptin receptor mutant), two distinct mouse models requiring neither chemical nor diet treatments to induce spontaneous decline of functional ß-cell mass promoting progressive diabetes development. Non-targeted metabolomics on ß-Phb2-/- mice identified 48 and 82 significantly affected metabolites in liver and plasma, respectively. Machine learning analysis pointed to deoxyhexose sugars consistently reduced at the asymptomatic pre-diabetic stage, including in db/db mice, showing strong correlation with the gradual loss of ß-cells. [...] Reference LI, Lingzi, et al. Metabolomics identifies a biomarker revealing in vivo loss of functional ß-cell mass before diabetes onset. Diabetes, 2019, vol. 68, no. 12, p. 2272-2286 PMID : 31537525 DOI : 10.2337/db19-0131 Available at: http://archive-ouverte.unige.ch/unige:126176 -
Methoxy-3-Veratryl-5,6-Dihydrobenzoglyoxalocoline T
HFTEROCYCLES. Vol 30, No I, 1990 PAPERS OF PROFESSOR TETSUJI KAMETANI 1 Studies on the Synthesis of Emetine and Related Compounds. VI. A Syn thesis of 4'. 5'-Methylenedioxy-6-[B-6". 7"-methylenedioxy-3"-methyl-py- tetrahydroisoquinolyl-I"] -ethyl]-4-methyl-3,4,5,6,7, B-hexahydro- ( 1 2 : 1.2-benzoquinolizine) S . Sugasawa and T . Kametani [Yakugaku Zasshi. 65, 372 - 373 (194511 2 Syntheses of Imidazoisoquinoline Derivatives. I. Synthesis of 9.10- Dimethoxy- 3- (p-aminophenyl)- -5.6-dihydrohenzoglyoxalocoline T . Kametani and H. Iida [ Yakugaku Zasshi, 70, 258 - 261 (19501 1 3 Syntheses of Imidazoisoquinoline Derivatives. 11. Synthesis of 9.10-Di- methoxy-3-veratryl-5,6-dihydrobenzoglyoxalocoline T. Kametani and H. Iwakata [ Yakugaku Zasshi, 70, 261 - 263 (1950) 1 4 Syntheses of Imidazoisoquinoline Derivatives. 111. Synthesis of 9.10-Di- methoxy- 3-safryl- 5.6-dihydrobenzoglyoxalocoline T . Kametani and H. Iwakata [Yakugaku Zasshi, 70. 263 - 265 (195011 5 Syntheses of Papaverine Derivatives. I. Synthesis of 1-(3'-Methoxy-4'- hydroxyphenyl) -3-methyl-6.7-methylenedioxyisoquinoline T. Kametani [ Yakugaku Zasshi, 71. 322 - 324 (1951) I 6 Syntheses of Imidazoisoquinoline Derivatives. IV. Syntheses of 9,lO- Methylenedioxy- 3- (4'-nitrophenyl) - 5-methyl- 5.6-dihydrobenzoglyoxalocoline. 9,lO-Methylenedioxy-3- (3', 4'-dimethoxypheny1)-5-methylbenzoglyoxalocoline and 9,lO-Methylenedioxy-3-( 3'. 4'-methylenedioxyphenyl]-5-methyl-5,6- dihydrobenzoglyo::alocoline T. Kametani, H. Iida, and H. Iwakata [ Yakugaku Zasshi. 71. 325- 329 (195111 Studies on the Syntheses of Aminoisoquinoline Derivatives. I. Saponification of Benzyl 1-Phenyl-6.7-dimethoxyisoquinoly1-3-carbamate T. Kametani [ Yakugaku Zasshi, 71. 329 - 331 (1951) I Studies on the Syntheses of Aminoisoquinoline Derivatives. -
(12) United States Patent (10) Patent No.: US 6,949,521 B2 Chu Et Al
USOO6949521B2 (12) United States Patent (10) Patent No.: US 6,949,521 B2 Chu et al. (45) Date of Patent: Sep. 27, 2005 (54) THERAPEUTICAZIDE COMPOUNDS Adamiak et al., “Synthesis of 6-Substituted Purines and ribonucleosides with N-(6-Purinyl)pyridinium Salts.” (75) Inventors: Chung K. Chu, Athens, GA (US); Angewandte Chemie, Intl. Ed., 24(12):1054–1055 (Dec., Lakshmi P. Kotra, Detroit, MI (US); 1985). Konstantine Manouilov, Omaha, NE Agarwal, R.P. et al., “Clinical Pharmacology of 9-3-D-Ara (US); Jinfa Du, Irvine, CA (US); binofuranosyladenine in Combination with 2'-Deoxycofor Raymond Schinazi, Decatur, GA (US) mycin,” Cancer Res., 42(9):3884–3886 (Sep., 1982). Anderson, B.D. et al., “Uptake Kinetics of 2',3'-Dideoxyi (73) Assignees: The University of Georgia Research nosine into Brain and Cerebrospinal Fluid of Rats: Intrave Foundation, Inc., Athens, GA (US); nous Infusion Studies,” J. Pharmacol. Exp. Ther., (1990) Emory University, Atlanta, GA (US) 253(1): 113–118. Andrei, G. et al., “Comparative Activity of Various Com (*) Notice: Subject to any disclaimer, the term of this pounds Against Clinical Strains of Herpes Simplex Virus,” patent is extended or adjusted under 35 Eur: J. Clin. Microbiol. Infect. Diseases, (1992) U.S.C. 154(b) by 396 days. 11(2):143–151. Balzarini, J. And DeClercq, E., “The Antiviral Activity of (21) Appl. No.: 09/849,870 9-B-D Arabinofuranosyladenine is Enhanced by the 2',3'-Dideoxyriboside, the 2',3'-Didehydro-2',3'-Dideox (22) Filed: May 4, 2001 yriboside and the 3'-Azido-2',3'-Dideoxyriboside of (65) Prior Publication Data 2,6-Diaminopurine,” Biochem. -
Novel Chemical Tools for the Modulation of Two Pore Channel 2
Dissertation zur Erlangung des Doktorgrades der Fakultät für Chemie und Pharmazie der Ludwig‐Maximilians‐Universität München NOVEL CHEMICAL TOOLS FOR THE MODULATION OF TWO PORE CHANNEL 2 Susanne Daniela Gerndt aus Schweinfurt 2020 Erklärung Diese Dissertation wurde im Sinne von § 7 der Promotionsordnung vom 28. November 2011 von Herrn Prof. Franz Bracher betreut. Eidesstattliche Versicherung Diese Dissertation wurde eigenständig und ohne unerlaubte Hilfe erarbeitet. München, den 29.06.2020 ____________________________ Susanne Daniela Gerndt Dissertation eingereicht am: 01.07.2020 1. Gutachter: Prof. Dr. Franz Bracher 2. Gutachter: Prof. Dr. Dr. Christian Grimm Mündliche Prüfung am 27.07.2020 Danksagung An dieser Stelle möchte ich mich ganz herzlich bei allen bedanken, die diese Arbeit durch viele große und kleine Beiträge erst ermöglicht haben: Allen voran Herrn Prof. Dr. Franz Bracher für dieses interessante und abwechslungsreiche Thema und seine stets großzügige Unterstützung und Förderung während der vergangenen Jahre. Ebenso bedanken möchte ich mich bei den Mitgliedern der Prüfungskommission, vor allem bei Prof. Dr. Dr. Christian Grimm, nicht nur für die freundliche Übernahme des Koreferats, sondern auch für die Möglichkeit mich in ein mir fachfremdes Thema einzuarbeiten und viel Neues zu lernen. Weiter möchte ich auch meinen Kooperationspartnern danken, sei es in München Frau Prof. Dr. Angelika Vollmar, in Leipzig Prof. Dr. Michael Schaefer oder anderswo. Bei den Mitarbeitern der Analytikabteilung der Chemie und Pharmazie bedanke ich mich auch recht herzlich für die zahlreichen Messungen und die Hilfe bei analytischen Fragestellungen. Einen herzlichen Dank richte ich auch an die Arbeitsgruppen Biel, Grimm und Schaefer, die mich im Rahmen gemeinsamer Kooperationen freundlich aufgenommen und unterstützt haben. -
Prevention and Reversal of Alzheimer's Disease Copyright © 2017 Ronald N
Prevention and Reversal of Alzheimer's Disease Copyright © 2017 Ronald N. Kostoff et al PREVENTION AND REVERSAL OF ALZHEIMER'S DISEASE by Ronald N. Kostoff a, Yi Zhang b , Jing Ma c, Alan L. Porter d, Henry. A. Buchtel e (a) Research Affiliate, School of Public Policy, Georgia Institute of Technology, USA (b) Post-Doctoral Researcher, Faculty of Engineering and Information Technology, University of Technology Sydney, Australia (c) Assistant Professor, College of Management, Shenzhen University, China (d) Professor Emeritus, School of Public Policy, Georgia Institute of Technology, USA (e) Associate Professor, Department of Psychiatry, University of Michigan, USA KEYWORDS Alzheimer's Disease; Dementia; Text Mining; Information Technology; Adverse Events; Risk Factors; Contributing Factors CITATION TO MONOGRAPH Kostoff RN, Zhang Y, Ma J, Porter AL, Buchtel HA. Prevention and reversal of Alzheimer's Disease. Georgia Institute of Technology. 2017. PDF. < https://smartech.gatech.edu/handle/1853/56646 > 1 Prevention and Reversal of Alzheimer's Disease Copyright © 2017 Ronald N. Kostoff et al COPYRIGHT AND CREATIVE COMMONS LICENSE COPYRIGHT Copyright © 2017 by Ronald N. Kostoff, Yi Zhang , Jing Ma, Alan L. Porter, Henry A. Buchtel Printed in the United States of America; First Printing, 2017 CREATIVE COMMONS LICENSE This work can be copied and redistributed in any medium or format provided that credit is given to the original author. For more details on the CC BY license, see: http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License<http://creativecommons.org/licenses/by/4.0/>. DISCLAIMERS The views in this monograph are solely those of the authors, and do not represent the views of the Georgia Institute of Technology, the University of Michigan, Shenzhen University, or the University of Technology Sydney. -
Permanently Charged Sodium and Calcium Channel Blockers As Anti-Inflammatory Agents
(19) TZZ ¥Z¥_T (11) EP 2 995 303 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 16.03.2016 Bulletin 2016/11 A61K 31/165 (2006.01) A61K 31/277 (2006.01) A61K 45/06 (2006.01) A61P 25/00 (2006.01) (2006.01) (2006.01) (21) Application number: 15002768.8 A61P 11/00 A61P 13/00 A61P 17/00 (2006.01) A61P 1/00 (2006.01) (2006.01) (2006.01) (22) Date of filing: 09.07.2010 A61P 27/02 A61P 29/00 A61P 37/08 (2006.01) (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • WOOLF, Clifford, J. GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Newton, MA 02458 (US) PL PT RO SE SI SK SM TR • BEAN, Bruce, P. Waban, MA 02468 (US) (30) Priority: 10.07.2009 US 224512 P (74) Representative: Lahrtz, Fritz (62) Document number(s) of the earlier application(s) in Isenbruck Bösl Hörschler LLP accordance with Art. 76 EPC: Patentanwälte 10797919.7 / 2 451 944 Prinzregentenstrasse 68 81675 München (DE) (71) Applicants: • President and Fellows of Harvard College Remarks: Cambridge, MA 02138 (US) This application was filed on 25-09-2015 as a • THE GENERAL HOSPITAL CORPORATION divisional application to the application mentioned Boston, MA 02114 (US) under INID code 62. • CHILDREN’S MEDICAL CENTER CORPORATION Boston, Massachusetts 02115 (US) (54) PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS (57) The present invention relates to a composition or a kit comprising N-methyl etidocaine for use in a method for treating neurogenic inflammation in a patient, wherein the kit further comprises instructions for use. -
Namenverzeichnis. Index of Names. Index Des Auteurs
Namenverzeichnis. Index of Names. Index des Auteurs. Kursiv gedruckte Seitenzahlen beziehen sich auf Literaturverzeichnisse. Page numbers printed in italic refer to References. Les chiffres en italique indiquent les pages de bibliographie. ABISCH, E. 107, 109, I38. ANDERSSON, C. O. 74, 76, 86. ABRAHAMS, P. 159, 175, 176, I94. ANDO, M. 118, 119, I42. ACHENBACH, H. 26, 27, 44, 45, 49, 50, ANDRES, W. W. 131, I44. 86, 97. ANGYAL, S. J. 154, 175, 180, 186, I92. ACKERMANN, D. 18o, I92. ANNER, G. III, I43. ADAMS, R. 189, I92, 332, 335, 336, 340, ANSELL, G. B. 154, 180, I92. 344, 345, 348, 358, 36o, 363, 365, 367, ANTONACCIO, L. D. 18, 27, 29, 37, 38, 369--371, 375, 379--381 , 383--386, 86, 90, 9I. 390, 391, 393, 396, 397, 40 3. AOKI, T. 125, 130, I44. ADELBERG, A. E. 364, 391, 405. APGAR, J. 412, 413, 435· ADHIKARI, S. K. 181, 184, I92. APLIN, R. T. 63, 65, 9I, 93, 238, 241, 270, ADKINS, A. L. 307, 309, 324. 275· ADLER, E. 321, 32I, 326. ApPEL, H. H. I92. AGRANOFF, B. W. 158, 176, 177, I92, I93, ApSIMON, J. W. 237, 238, 273, 275· I95· ARENDARUK, A. P. 335, 374, 382, 386, AGUAYO BRISSOLESE, J. 18, 27, 31, 42, 388, 391, 397· 9I , 92 . ARESHKINA, L. VA. 374, 397. AHLUWALIA, V. K. 261, 275. ARGOUDELIS, A. D. 183, I92, 203. AHMANN, C. F. 381, 395. ARIGONI, D. 116, 129, I38. AHMED, Q. A. 181, 202. ARISON, B. 318, 320, 328. AHOND, A. 236, 272, 275. ARNDT, R. R. 40, 55, 86, 94· AHUJA, J. -
(12) Patent Application Publication (10) Pub. No.: US 2012/0172429 A1 Woolf Et Al
US 2012O172429A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0172429 A1 Woolf et al. (43) Pub. Date: Jul. 5, 2012 (54) PERMANENTLY CHARGED SODUMAND Publication Classification CALCUMI CHANNEL BLOCKERS AS ANT (51) Int. Cl. NFLAMMLATORY AGENTS A 6LX 3L/277 (2006.01) C07C 237/14 (2006.01) (76) Inventors: Clifford J. Woolf, Newton, MA C07C 255/33 (2006.01) (US); Bruce P. Bean, Waban, MA A6IP 25/00 (2006.01) (US) A6IP 29/00 (2006.01) A6IP II/06 (2006.01) A6IP II/IO (2006.01) (21) Appl. No.: 13/382,834 A6IP 9/02 (2006.01) A6IP 700 (2006.01) (22) PCT Fled: Jul. 9, 2010 A6IPI/00 (2006.01) A6IPI3/02 (2006.01) (86) PCT NO.: PCT/US 10/41537 A6IP 25/06 (2006.01) A6IP 7/06 (2006.01) S371 (c)(1), A6IP II/02 (2006.01) (2), (4) Date: Mar. 26, 2012 A6II 3/16 (2006.01) (52) U.S. Cl. .......... 514/523: 514/626:564/194; 558/408 Related U.S. Application Data (57) ABSTRACT (60) Provisional application No. 61/224,512, filed on Jul. The invention provides compounds, compositions, methods, 10, 2009. and kits for the treatment of neurogenic inflammation. Patent Application Publication US 2012/0172429 A1 7Z089||Z0897ZZOZ7Z euu||(SunO?) 3.Infi!--| Patent Application Publication Jul. 5, 2012 Sheet 2 of 2 US 2012/0172429 A1 Figure 2 1 uM Capsaicin - Before - After (3 min Wash) 1 uM Capsaicin +300 uMN-methyl-verapamil After (3 min Wash) US 2012/0172429 A1 Jul. 5, 2012 PERMANENTLY CHARGED SODUMAND of a compound that is capable of entering a nociceptor CALCUMI CHANNEL BLOCKERS AS ANT through a channel-forming receptor present in the nociceptor NFLAMMLATORY AGENTS when the receptor is activated and inhibiting a Voltage-gated ion channel present in the nociceptor, wherein the compound CROSS-REFERENCE TO RELATED does not substantially inhibit said channel when applied to the APPLICATIONS extracellular face of the channel and when the receptor is not 0001. -
Recent Progress on Biological Activity of Amaryllidaceae and Further Isoquinoline Alkaloids in Connection with Alzheimer’S Disease
molecules Review Recent Progress on Biological Activity of Amaryllidaceae and Further Isoquinoline Alkaloids in Connection with Alzheimer’s Disease Lucie Cahlíková 1,* , Rudolf Vrabec 2, Filip Pidaný 1, Rozálie Peˇrinová 1, Negar Maafi 1 , Abdullah Al Mamun 1 , Aneta Ritomská 1, Viriyanata Wijaya 1 and Gerald Blunden 3 1 ADINACO Research Group, Department of Pharmaceutical Botany, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic; [email protected] (F.P.); [email protected] (R.P.); [email protected] (N.M.); [email protected] (A.A.M.); [email protected] (A.R.); [email protected] (V.W.) 2 Department of Pharmacognosy, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic; [email protected] 3 School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, Hampshire P01 2DT, UK; [email protected] * Correspondence: [email protected]; Tel.: +420-495-067-311 Abstract: Alzheimer’s disease (AD) is a progressive age-related neurodegenerative disease recog- nized as the most common form of dementia among elderly people. Due to the fact that the exact pathogenesis of AD still remains to be fully elucidated, the treatment is only symptomatic and available drugs are not able to modify AD progression. Considering the increase in life expectancy worldwide, AD rates are predicted to increase enormously, and thus the search for new AD drugs is Citation: Cahlíková, L.; Vrabec, R.; urgently needed. Due to their complex nitrogen-containing structures, alkaloids are considered to be Pidaný, F.; Peˇrinová,R.; Maafi, N.; promising candidates for use in the treatment of AD. -
Osteoarthritis Guideline Appendix 4 – Search Strategies
SUPPLEMENTARY APPENDIX 4: Search Strategies ACR/AF 2019 Guideline for the Management of Osteoarthritis of the Hand, Hip and Knee OSTEOARTHRITIS Original searches were run from inception of databases to 10/15/17. Updates were run from 10/15/17 to 8/1/18. PUBMED Syntax Guide for PubMed [MeSH] = Medical Subject Heading [Text Word] = Includes all words and numbers in the title, abstract, other abstract, MeSH terms, MeSH Subheadings, Publication Types, Substance Names, Personal Name as Subject, Corporate Author, Secondary Source, Comment/Correction Notes, and Other Terms - typically non-MeSH subject terms (keywords)…assigned by an organization other than NLM [MeSH subheading] = a Medical Subject [Title/Abstract] = Includes words in the title Heading subheading, e.g.